474 results about "Polyhydroxybutyrate" patented technology

The present invention provides polymers made by genetically engineering microorganisms for making a self-retaining suture. In an embodiment of the present invention the genetically engineering microorganisms synthesize polyhydroxyalkanoate (PHA) polymers. In an alternate embodiment of the invention, the genetically engineering microorganisms synthesize polybetahydroxybutyrate (PHB) polymers. In an alternative embodiment of the invention, the self-retaining sutures can be made from a copolymer such as polyhydroxybutyratevalerate (PHBV), where the genetically engineering microorganisms produces PHA polymers as the monofilament base material and a different genetically engineering microorganisms produces polyhydroxybutyratevalerate (PHBV) polymers. In various embodiments of the invention, recombinant expressed self-retaining suture materials have a melting point in the range from between approximately 40° C. to approximately 180° C. In various embodiments of the invention, recombinant expressed self-retaining suture materials have extension-to-break strength of between approximately 8% and approximately 42%.

Disclosed is an occluder for closing an intracardiac defect, such as a patent foramen ovale (PFO), and a method for making the same. The occluder includes a frame and at least one scaffold which are formed from a bioabsorbable polymer, such as poly-4-hydroxybutyrate. The surface of the frame and scaffold are textured to promote cell attachment. Texturing of the surface can be achieved by any number of mechanical or chemical procedures. The device is coated with collagen and heparin which are covalently bound to the surface of the device. The occluder provides improved defect closure compared to other septal occluders known in the art. In particular, the occluder described is specifically designed to improve host cell attachment to and tissue ingrowth over the device when implanted in a patient as compared to the level of host cell attachment and tissue ingrowth achieved with other implantable devices made of bioabsorbable polymers.

A new embolic agent, bioabsorbable polymeric material (BPM) is incorporated to a Guglielmi detachable coil (GDC) to improve long-term anatomic results in the endovascular treatment of intracranial aneurysms. The embolic agent, comprised at least in part of at least one biocompatible and bioabsorbable polymer and growth factors, is carried by hybrid bioactive coils and is used to accelerate histopathologic transformation of unorganized clot into fibrous connective tissue in experimental aneurysms. An endovascular cellular manipulation and inflammatory response are elicited from implantation in a vascular compartment or any intraluminal location. Thrombogenicity of the biocompatible and bioabsorbable polymer is controlled by the composition of the polymer. The coil further is comprised at least in part of a growth factor or more particularly a vascular endothelial growth factor, a basic fibroblast growth factor or other growth factors. The biocompatible and bioabsorbable polymer is in the illustrated embodiment at least one polymer selected from the group consisting of polyglycolic acid, poly~glycolic acid/poly-L-lactic acid copolymers, polycaprolactive, polyhydroxybutyrate/hydroxyvalerate copolymers, poly-L-lactide. Polydioxanone, polycarbonates, and polyanhydrides.

Specific polymer blends of polylactic acid (PLA) and polyhydroxybutyrate (PHB) and poly-(butylenes adipate-co-terephthalate (PBAT) as a fatty acid quaternary ammonium modified clay. The blends are particularly useful for barrier packaging.

The present invention refers to a polymeric composition prepared from a biodegradable polymer defined by poly-hydroxybutyrate (PHB) or copolymers thereof, and at least one other biodegradable polymer, such as polycaprolactone (PCL) and poly (lactic acid) (PLA), so as to alter its structure, and further at least one additive of the type of natural filler and natural fibers, and, optionally, nucleant, thermal stabilizer, processing aid, with the object of preparing an environmentally degradable material. According to the production process described herein, the composition resulting from the mixture of the modified biodegradable polymer and additives can be utilized in the manufacture of injected packages for food products, injected packages for cosmetics, tubes, technical pieces and several injected products.

The invention relates to a polylactic acid foamed material and a preparation method thereof. The invention solves the technical problems of large pore size, nonuniformity and high porosity in the existing product. The polylactic acid foamed material is prepared by an extrusion foaming method. The polylactic acid foamed material comprises polylactic acid, at least one biodegradable polyester (selected from poly(butylenes succinate), polyhydroxybutyrate, polycaprolactone and copolymer or blend thereof), a physical foaming agent, and at least one processing assistant for foaming. The apparent density of the microporous foamed sheet is 0.05-0.5g/cm<3>, the average pore diameter is not greater than 100 micrometers, and the porosity is not greater than 10%. The invention is mainly used in the fields of food packaging, automobile industry and the like.

Absorbable implants for breast surgery that conform to the breast parenchyma and surrounding chest wall have been developed. These implants support newly lifted breast parenchyma, and/or a breast implant. The implants have mechanical properties sufficient to support a reconstructed breast, and allow the in-growth of tissue into the implant as it degrades. The implants have a strength retention profile allowing the support of the breast to be transitioned from the implant to regenerated host tissue, without significant loss of support. Three-dimensional implants for use in minimally invasive mastopexy/breast reconstruction procedures are also described, that confer shape to a patient's breast. These implants are self-reinforced, can be temporarily deformed, implanted in a suitably dissected tissue plane, and resume their preformed three-dimensional shape. The implants are preferably made from poly-4-hydroxybutyrate (P4HB) and copolymers thereof. The implants have suture pullout strengths that can resist the mechanical loads exerted on the reconstructed breast.

Described herein are biodegradable compositions, methods for making these compositions, and applications using these compositions. In one embodiment, a process of manufacturing paper or other products is provided using a composition comprising a mixture of 25% to 80% calcium carbonate along with a biodegradable biopolymer matrix made from renewable resources including polylactic acid (“PLA”), soy proteins, polyhydroxyalkanoate (“PHA”), polyhydroxybutyrate (“PHB”), and/or starch from corn, wheat, tapioca, potatoes, or similar renewable resource products.

Methods for engineering transgenic organisms that synthesize polyhydroxyalkanoates (PHAs) containing 3-hydroxyhexanoate as comonomer have been developed. These processes are based on genetically engineered bacteria such as Escherichia coli or in plant crops as production systems which include PHA biosynthetic genes from PHA producers. In a preferred embodiment of the method, additional genes are introduced in wild type or transgenic polyhydroxybutyrate (PHB) producers, thereby creating new strains that synthesize 3HH monomers which are incorporated into PHAs. The 3HH monomer preferably is derived in microbial systems using butanol or butyrate as feedstocks, which are precursors of 3-hydroxyhexanoyl-CoA. Pathways for in vivo production of butyrol-CoA specifically encompassing butyryl-CoA dehydrogenase activity are provided.

The invention belongs to a manufacturer method for thermal resistant easy to machined poly lactic acid resin that is made up from poly lactic acid, thermal resistant material, high molten mass speed polymers material aliphatic polyester and antioxidant. The process includes mixing in blending machine, and extruding at 160-185 degree centigrade. The resin could be used to make film, panel, sheet material, sparkle, and plastic components. The products have excellent thermal resistance capability, mechanical property and machine property.

The invention relates to a total biodegradable non-woven fabric material which is produced by adding 10 to 40 percent of low molecular weight carbon dioxide-cyclohexene oxide copolymer or 10 to 40 percent of high molecular weight poly L-polylactic acid or 10 to 40 percent of poly-hydroxylic butyrate to biodegradable carbon dioxide-propylene oxide or carbon dioxide-epoxy ethane copolymer materials, thus improving the dimensional stability of the carbon dioxide copolymer under high temperature. The number average molecular weight of the carbon dioxide-cyclohexene oxide copolymer is between 4000 and 8000 and the number average molecular weight of the poly L-polylactic acid is above 100,000. By using the carbon dioxide copolymer material of the invention, manufacture can be carried out by adopting a spun-bond method which is commonly used in non-woven fabric manufacturing technique. The obtained non-woven fabrics can maintain dimensional stability at the temperature between 70 DEG C and 75 DEG C, have biodegradation characteristics under the situation of composts or landfill with carbon dioxide and water as degradation end products, and cannot pollute environment when being burnt.

The environmentally degradable polymeric composition is obtained from the biodegradable polymers poly (hydroxybutyrate)-PHB and copolymers thereof and poly (lactic acid)-PLA and, optionally, at least one of the additives defined by: plasticizer of natural origin, such as natural fibers; natural fillers; thermal stabilizer; nucleant; compatibilizer; surface treatment agent; and processing aid.

A method of selection for type II methanotrophs is provided that includes enriching a microbial feedstock using a non-sterile bioreactor with a methane source and a nitrogen source, where the microbial feedstock includes a mixture of Type I and Type II methanotrophic cells, where an inhibited growth of the Type I methanotrophic cells and an enhanced growth of the Type II methanotrophic cells forms. The method further includes exposing intermittently the enriched microbial feedstock to i) nitrate, ii) urea, or i) and ii), where enhanced growth of the Type II methanotrophs is established, and exposing the Type II methanotrophs to an unbalanced growth condition where production of polyhydroxybutyrate is induced.

The invention relates to mutant strains of the genus Sphingomonas which have a mutation in at least one gene encoding a protein involved in polyhydroxybutyrate (“PHB”) synthesis that allows the mutant strains to produce PHB-deficient sphingans. The invention is also directed to a process for preparing a clarified sphingan solution comprising heating aqueous sphingan solution, in particular PHB-deficient sphingan solution, to a clarification temperature of about 30° C. to about 70° C., and treating the solution with a clarification agent and enzymes. In addition, the invention is directed to a food or industrial product comprising a PHB-deficient and/or clarified sphingan. One particular embodiment of the invention is directed to a clarified, PHB-deficient high-acyl gellan and the processes of making thereof.

Absorbable particles which comprises poly-4-hydroxybutyrate and/or its copolymers are formulated in injectable suspension suitable for prophylactic or therapeutic embolization, which comprises administering to a human or animal the injectable suspension process for producing particles of the poly-4-hydroxybutyrate and/or its copolymer.